{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Cancer&page=61",
    "query": {
      "condition": "Ovarian Cancer",
      "page": 61
    },
    "page_size": 10
  },
  "pagination": {
    "page": 61,
    "page_size": 10,
    "total_count": 2470,
    "total_pages": 247,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Cancer&page=62&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Cancer&page=60&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-05T16:00:00.496Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05062174",
      "title": "Breast Cancer BRCA1 Carriers: a Pilot Study",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "BRCA1 Mutation",
        "High-grade Serous Ovarian Cancer",
        "TNBC - Triple-Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Mifepristone 200 MG",
          "type": "DRUG"
        },
        {
          "name": "Prophylactic mastectomy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2021-11-01",
      "completion_date": "2024-12-31",
      "has_results": false,
      "last_update_posted_date": "2022-12-15",
      "last_synced_at": "2026-11-05T16:00:00.496Z",
      "location_count": 2,
      "location_summary": "Carmel, Indiana • Indianapolis, Indiana",
      "locations": [
        {
          "city": "Carmel",
          "state": "Indiana"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05062174"
    },
    {
      "nct_id": "NCT00003297",
      "title": "Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "mitoxantrone hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "thiotepa",
          "type": "DRUG"
        },
        {
          "name": "topotecan hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Georgetown University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 50,
      "start_date": "1997-12",
      "completion_date": "2001-01",
      "has_results": false,
      "last_update_posted_date": "2011-03-24",
      "last_synced_at": "2026-11-05T16:00:00.496Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003297"
    },
    {
      "nct_id": "NCT02374827",
      "title": "Salpingectomy at Cesarean Delivery for Ovarian Cancer Reduction (SCORE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Standard postpartum tubal ligation",
          "type": "PROCEDURE"
        },
        {
          "name": "Complete Salpingectomy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "25 Years and older · Female only"
      },
      "enrollment_count": 80,
      "start_date": "2015-04",
      "completion_date": "2017-09",
      "has_results": false,
      "last_update_posted_date": "2017-10-05",
      "last_synced_at": "2026-11-05T16:00:00.496Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02374827"
    },
    {
      "nct_id": "NCT03326713",
      "title": "Genetic Risk Assessment for Cancer Education and Empowerment (GRACE) Project",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Telephone Counseling & Navigation (TCN)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Mailed Targeted Print (TP)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Usual Care (UC)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "Rutgers, The State University of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "21 Years and older · Female only"
      },
      "enrollment_count": 668,
      "start_date": "2017-11-02",
      "completion_date": "2022-06-02",
      "has_results": true,
      "last_update_posted_date": "2026-06-25",
      "last_synced_at": "2026-11-05T16:00:00.496Z",
      "location_count": 1,
      "location_summary": "New Brunswick, New Jersey",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03326713"
    },
    {
      "nct_id": "NCT00003103",
      "title": "Chemotherapy in Treating Patients With Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer",
        "Breast Cancer",
        "Colorectal Cancer",
        "Esophageal Cancer",
        "Head and Neck Cancer",
        "Kidney Cancer",
        "Lung Cancer",
        "Ovarian Cancer",
        "Prostate Cancer",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "oblimersen sodium",
          "type": "BIOLOGICAL"
        },
        {
          "name": "docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 57,
      "start_date": "1997-08",
      "completion_date": "2002-08",
      "has_results": false,
      "last_update_posted_date": "2013-07-03",
      "last_synced_at": "2026-11-05T16:00:00.496Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003103"
    },
    {
      "nct_id": "NCT06973161",
      "title": "ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Bladder Cancer",
        "Biliary Tract Cancer",
        "Cervical Cancer",
        "Endometrial Cancer",
        "Ovarian Cancer",
        "Pancreatic Cancer",
        "Colorectal Cancer",
        "Lung Cancer",
        "Other Tumors"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 140,
      "start_date": "2025-06-10",
      "completion_date": "2026-03-17",
      "has_results": false,
      "last_update_posted_date": "2026-04-08",
      "last_synced_at": "2026-11-05T16:00:00.496Z",
      "location_count": 2,
      "location_summary": "Spartanburg, South Carolina • Houston, Texas",
      "locations": [
        {
          "city": "Spartanburg",
          "state": "South Carolina"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06973161"
    },
    {
      "nct_id": "NCT03601897",
      "title": "A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced or Metastatic Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Rebastinib",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Deciphera Pharmaceuticals, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 177,
      "start_date": "2018-10-25",
      "completion_date": "2022-05-23",
      "has_results": true,
      "last_update_posted_date": "2024-12-27",
      "last_synced_at": "2026-11-05T16:00:00.496Z",
      "location_count": 14,
      "location_summary": "Birmingham, Alabama • Aurora, Colorado • Chicago, Illinois + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03601897"
    },
    {
      "nct_id": "NCT03297424",
      "title": "A Study of PLX2853 in Advanced Malignancies.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Small Cell Lung Cancer",
        "Uveal Melanoma",
        "Ovarian Clear Cell Carcinoma",
        "Non-Hodgkin Lymphoma",
        "Advanced Malignancies",
        "Solid Tumor",
        "Diffuse Large B Cell Lymphoma",
        "Follicular Lymphoma"
      ],
      "interventions": [
        {
          "name": "PLX2853",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Opna Bio LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2017-09-12",
      "completion_date": "2021-06-07",
      "has_results": false,
      "last_update_posted_date": "2022-07-25",
      "last_synced_at": "2026-11-05T16:00:00.496Z",
      "location_count": 5,
      "location_summary": "Scottsdale, Arizona • Miami, Florida • New York, New York + 2 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03297424"
    },
    {
      "nct_id": "NCT05601752",
      "title": "ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Autologous genetically modified ADP-A2M4CD8 cells",
          "type": "GENETIC"
        },
        {
          "name": "Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "USWM CT, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 75 Years · Female only"
      },
      "enrollment_count": 21,
      "start_date": "2023-06-26",
      "completion_date": "2026-09-24",
      "has_results": false,
      "last_update_posted_date": "2026-10-19",
      "last_synced_at": "2026-11-05T16:00:00.496Z",
      "location_count": 9,
      "location_summary": "Scottsdale, Arizona • Duarte, California • Augusta, Georgia + 6 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05601752"
    },
    {
      "nct_id": "NCT04701645",
      "title": "Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Peritoneal Cancer",
        "Ovarian Cancer Stage III",
        "Ovarian Cancer Stage IV",
        "Fallopian Tube Cancer Stage IV",
        "Fallopian Tube Cancer Stage III"
      ],
      "interventions": [
        {
          "name": "Microdevice",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 20,
      "start_date": "2022-11-01",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-18",
      "last_synced_at": "2026-11-05T16:00:00.496Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04701645"
    }
  ]
}